Navigation Links
International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma
Date:5/24/2013

LOS ANGELES, May 24, 2013 /PRNewswire/ -- An international roster of experts on malignant pleural mesothelioma (MPM) gathered on Saturday, May 18, in Santa Monica, Calif., to discuss their latest research findings on new lung-sparing therapies for MPM, a rare form of cancer that results from exposure to asbestos and commonly affects the pleura, the lining of the chest.

Hosted by UCLA and the Pacific Heart, Lung and Blood Institute, the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma focused on research aimed at preserving vital lung function in MPM patients. Mesothelioma experts now agree that extrapleural pneumonectomy, which involves removal of the lung and surrounding diseased tissues, does not have a place in treatment of patients with this asbestos-related problem. Presentations included the latest surgical techniques for removal of cancerous tumors and a variety of adjunctive techniques.

Symposium leader, Robert B. Cameron , MD, FACS, Director of the UCLA Mesothelioma Comprehensive Research Program and Chief of Thoracic Surgery at the West Los Angeles VA Medical Center, presented treatment strategies and results of multimodality treatment of patients with sarcomatoid-type MPM, the fastest spreading and most difficult to treat form of the disease. He also discussed current thermal research at UCLA and the effectiveness of cryoablation in killing MPM cancer cells.

The symposium's distinguished faculty included Joseph S. Friedberg , MD, of the University of Pennsylvania, who presented promising new photodynamic therapy results using light to directly kill cancer cells; Olga Olevsky , MD, of UCLA Medical Center, who discussed results of a variety of novel treatment strategies; Italian Radiologist Marco Trovo, MD, who presented the early results of tomotherapy techniques following pleurectomy; and Raffit Hassan, MD, of the National Cancer Institute, who discussed anti-mesothelin agents for mesothelioma therapy.

"There were a number of incredibly exciting studies that far exceed what we've seen before," said Dr. Cameron. "All of our collective efforts are finally beginning to pay off in new treatments that truly affect patients."

This CME-granting event, which was held at the Sheraton Delfina Hotel, was attended by physicians, nurses, other medical professionals, as well as mesothelioma patients and others with an interest in advances in MPM treatments.

About The Pacific Meso Center

The Pacific Meso Center (PMC) is a division of the Pacific Heath, Lung & Blood Institute, a 501(c)3 nonprofit medical research institute established in 2002, which is focused on the treatment and prevention of malignant pleural mesothelioma (MPM). The exploration of innovative ideas forms the foundation of PMC's unique research program and provides the promise of future treatment breakthroughs. PMC is dedicated to educating the public on asbestos-related disease and informing them of their treatment options. PMC also connects newly diagnosed patients with patients that have been trough treatment and provides assistance and emotional support.

For further information, please contact:

Robert B. Cameron , M.D. 
Professor of Cardiothoracic Surgery and Surgical Oncology
Director, UCLA Comprehensive Mesothelioma Program
David Geffen School of Medicine at UCLA
10780 Santa Monica Boulevard
Suite 100
Los Angeles, CA 90025-7613
(310) 470-8980 (voice)
(310) 470-3742 (fax)
Email

Contact: 
Clare Cameron
310-478-4678

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

 


'/>"/>
SOURCE The Pacific Meso Center
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
4. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
5. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
6. Chindex International, Inc. to Report First Quarter 2012 Financial Results
7. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
8. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
9. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
10. Bacterin International Signs Its Third National GPO Contract with Novation
11. SurgLine International, Inc. Chief Executive Officer, Thomas Toland, Exclusive Interview on Stock Traders Talk Radio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
(Date:2/11/2016)... 11, 2016 Stem cells are primitive cells ... self-renewal and the capacity to differentiate into mature cell ... as the first mouse embryonic stem cells were derived ... 1995 that the first culturing of embryonic stem cells ... not produced until 2006 As a result of these ...
(Date:2/11/2016)... -- Kindred Biosciences, Inc. (NASDAQ: KIN ), a biopharmaceutical ... pets, today announced the submission to FDA of the ... (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline results ... the control of pyrexia (fever) in horses were recently ... --> The Chemistry, Manufacturing, and Controls technical ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare ... San Francisco General Hospital on April 5-7. The series is a multi-day, multi-workshop ... habits. The workshops cover a broad range of topics, including coaching skills, the ...
(Date:2/12/2016)... ... , ... The Jones Agency, a family owned insurance company with offices serving ... charity drive with the Tarrant Area Food Bank in the hopes of alleviating hunger ... need, the Tarrant County Food Bank offers hope and security to the one in ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Miami Dental Specialists ... to their Miami dental office. Beginning in January, Miami Dental Specialists will offer ... Dental Specialists are the first office to be chosen by the dental implant manufacturer, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information Services, Inc. (AIS) ... PBMs,” an upcoming Feb. 24 webinar that will discuss ways health plans and ... such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors to ...
(Date:2/12/2016)... ... ... The Central Coast Autism Spectrum Center (CCASC) invites teens ages 11-18 to its annual Winter ... teens with and without special needs to gather in a safe and supportive environment. Volunteers ... will take place on Saturday, Feb. 13 from 7 to 9:30 p.m. at Elks Lodge, ...
Breaking Medicine News(10 mins):